Adolore BioTherapeutics Publishes Promising Preclinical Data on Non-Opioid Analgesic Gene Therapy

Adolore BioTherapeutics has announced strong preclinical results for its non-opioid analgesic gene therapy, ADLR-1001, designed to treat chronic knee pain caused by osteoarthritis (OA). These findings validate the company's method of delivering a non-opioid analgesic minigene to targeted sensory neurons through local administration.

The data provide robust proof-of-concept for ADLR-1001, showing prolonged therapeutic effects and indicating a significant reduction in chronic knee pain due to OA. These effects were achieved via the activation of Kv7 voltage-gated potassium channels in small sensory neurons.

Importantly, the study observed no adverse events, and animals treated with ADLR-1001 exhibited normalized weight-bearing and activity levels. The company is set to continue development with support from an NIH/NINDS UH3 HEAL Grant, aiming for clinical studies by 2026.